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Abstract
Background: Tumor necrosis factor alpha (TNFa) has been used to treat certain tumors in clinic trials. However,
the curative effect of TNFa has been undermined by the induced-NF-B activation in many types of tumor.
Maslinic acid (MA), a pharmacological safe natural product, has been known for its important effects as anti-
oxidant, anti-inflammatory, and anti-viral activities. The aim of this study was to determine whether MA potentiates
the anti-tumor activity of TNFa though the regulation of NF-B activation.
Results: In this study, we demonstrate that MA significantly enhanced TNFa-induced inhibition of pancreatic
cancer cell proliferation, invasion, and potentiated TNFa-induced cell apoptosis by suppressing TNFa-induced NF-
B activation in a dose- and time-dependent manner. Addition of MA inhibited TNFa-induced IBa degradation,
p65 phosphorylation, and nuclear translocation. Furthermore, MA decreased the expression levels of NF-B-
regulated genes, including genes involved in tumor cell proliferation (Cyclin D1, COX-2 and c-Myc), apoptosis
(Survivin, Bcl-2, Bcl-xl, XIAP, IAP-1), invasion (MMP-9 and ICAM-1), and angiogenesis (VEGF). In athymic nu/nu mouse
model, we further demonstrated that MA significantly suppressed pancreatic tumor growth, induced tumor
apoptosis, and inhibited NF-B-regulated anti-apoptotic gene expression, such as Survivin and Bcl-xl.
Conclusions: Our data demonstrate that MA can potentiate the anti-tumor activities of TNFa and inhibit
pancreatic tumor growth and invasion by activating caspase-dependent apoptotic pathway and by suppressing
NF-B activation and its downstream gene expression. Therefore, MA together with TNFa could be new promising
agents in the treatment of pancreatic cancer.
Background
Pancreatic cancer is an exceptionally devastating and
incurable disease, which is becoming the fourth killer of
patients with cancer [1] It was estimated that 34,300
people died of pancreatic cancer in the United States
and 40,000 in Europe in 2008 alone [1,2]. The treatment
of pancreatic cancer has largely been unsuccessful due
to its uncontrolled growth, high rate metastasis, and
common resistance to conventional approaches includ-
ing surgery, radiation and/or chemotherapy [3-5].
Therefore, there is a need for development of new and
effective chemotherapeutic agents, which can target
multiple signaling pathways to induce responsiveness of
pancreatic cancer cells to death signals [6,7].
TNFa, a key proinflammatory factor, has been shown
to have anti-tumor activity in several preclinical models
and in non-comparative clinical trials [8-12]. However,
the curative effect seems not perfect as anticipated due
to its systemic cytotoxicities and resistance to tumor
cells, which prevents TNFa from becoming an effective
anticancer agent [10,13]. Recent studies have shown that
the abnormal activation of NF-B is the main reason for
TNFa tolerance in many types of tumor [8,10,13,14].
When binding to its receptor (tumor necrosis factor
receptor, TNFR) on the cells, TNFa can induce apopto-
sis via recruiting TNFR-associated death domain protein
(TRADD), FADD, and Caspase-8, and then modulate
Caspase-9 and Caspase-3. The activated Caspase-3 can
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induce poly (ADP-ribose) polymerase (PARP) cleavage
and switch on cell apoptosis programs. On the other
hand, bound receptor TNFR has been shown to activate
IBa kinase (IKK). IKK, in turn, phosphorylates the
IBa protein, resulting in the ubiquitination and disso-
ciation of IBa from NF-B complex, and eventually
leading to the degradation of IBa by the proteosome.
The activated NF-B is then translocated into the
nucleus where it binds to specific sequences of DNA
and activates the expression of some anti-apoptosis
genes, such as Bcl-2, Survivin, XIAP, and IAPs [15,16].
Therefore, agents that can suppress TNFa-induced NF-
B activation, and at the same time enhance TNFa-
induced cell apoptotic activation will significantly
improve the anti-tumor activities of TNFa [8,10,13].
Natural products have been a successful source of
therapeutic agents and drug leads. MA, a pentacyclic tri-
terpene acid, is widely present in dietary plants, espe-
cially abundant in olive fruit skins. The compound has
attracted much interest due to its proven pharmacologi-
cal safety and its many biological activities such as anti-
inflammation[17], anti-virus [18], anti-oxidation [17,19],
and anti-diabetogenic activities [20,21]. Recently, some
studies have shown that MA has moderate anti-cancer
activities in colon cancer [22] and astrocytoma cell [23].
However, the mechanisms of MA action in inflamma-
tion and cancers are still not clear, and the synergistic
effects of MA and TNFa in inhibiting tumor growth
and proliferation have not been investigated.
In this study, we demonstrated that MA greatly poten-
tiated the inhibitory effect of TNFa on the growth of
pancreatic cancer through activation of apoptosis. MA
activates TNFa-induced caspase and PARP apoptotic
signaling pathway while suppresses TNFa-induced NF-
B activation in a dose-dependent manner. Moreover,
MA inhibited TNFa-induced IBa degradation, p65
phosphorylation and nuclear translocation, as well as
NF-B mediated gene expression. Finally, in vivo athy-
mic nu/nu mouse model, MA suppressed pancreatic
tumor growth and induced tumor cell apoptosis by inhi-
biting NF-B-regulated anti-apoptosis genes, such as
Survivin and Bcl-xl. Therefore, our results demonstrated
that MA potentiated the efficacy of TNFa susceptibility
to pancreatic tumor by enhancing caspase apoptotic sig-
naling pathway and by inhibiting NF-B activation and
its down-stream gene expression.
Results
MA enhanced TNFa-mediated inhibition of pancreatic
cancer cell proliferation
To determine the effects of MA (Fig. 1A), a recently dis-
covered triterpenoid isolated as the main compound
from olive-skin pomace on pancreatic cancer cell
growth, we treated Panc-28 pancreatic cancer cells with
different concentration of TNFa, MA or together and
then measured cell proliferation by MTS assay. Our
data indicated that TNFa or MA alone only had moder-
ate inhibitory effect on the growth of Panc-28 cells (Fig.
1B, White dot). However, in the presence of a non-
growth inhibitory dose of TNFa (0.1 nM) or MA (10
microM), MA together with TNFa was highly effective
on Panc-28 cells proliferation in a dose-dependent man-
ner (Fig. 1B, black dot). Similar effects were also
observed in 2 other pancreatic cancer cell lines, AsPC-1
and BxPC-3 (Fig. 1C), suggesting that MA is an effective
agent in suppressing pancreatic cancer cell proliferation
in the presence of TNFa. These results showed that
MA and TNFa together could effectively suppress pan-
creatic cancer cell growth.
MA potentiates pancreatic cancer cell apoptosis induced
by TNFa
To understand how MA suppressed pancreatic cancer
cell proliferation, we examined whether MA affected the
viability of pancreatic cancer cells by Live/Dead assays,
which determines intracellular esterase activity and
membrane integrity to identify live or dead cells. As
shown in Fig. 2A, TNFa alone induced cell death from
2 ± 1.02% to 4 ± 1.31% (red signal), and MA alone
induced cell death from 2 ± 1.02% to 27 ± 3.58%. When
used together, MA and TNFa synergistically induced
cell death to 56 ± 5.34% in Panc-28 cells, indicating that
MA can significantly decrease pancreatic cancer cell via-
bility induced by TNFa in vitro.
To further examine whether the cytotoxicity of MA
was caused through cell apoptosis, we analyzed the
apoptotic effect of MA using Annexin V staining and
TUNEL assay. The Annexin V staining determines the
early apoptosis events, in which the membrane phos-
pholipid phosphatidylserine moves from cell cytoplasmic
interface to the extracellular surface [16]. Our data indi-
cated that MA together with TNFa potentiated cell
apoptosis from 6.0 ± 2.01% to 51 ± 5.32% in pancreatic
cancer cells (Fig. 2B, top). Similar results were obtained
by TUNEL assay, in which MA enhanced TNFa-
induced apoptosis from 7.7 ± 0.89% to 32.2 ± 0.98%,
suggesting a synergistic effect of MA with TNFa in
inducing cell apoptosis (Fig. 2B, bottom). Therefore, our
results demonstrated that combination of MA with
TNFa could significantly affect pancreatic cancer cell
viability and induce cancer cell apoptosis.
MA potentiates the TNFa-induced activation of caspase-3
and PARP in pancreatic cancer cells
To confirm the synergistic effect of MA and TNFa on
cell apoptosis, we examined wheather MA affects
TNFa-induced activation of caspase apoptotic pathway
in pancreatic cancer cells by measuring the marker
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Figure 1 MA enhances cell proliferation inhibition mediated by TNFa. (A) Structure of Maslinic Acid (MA) [(2a, 3b)-2, 3-dihydroxyolean-12-
en-28-oic acid]. (B) MA potentiates TNFa-mediated cell growth inhibitory in different pancreatic cancer cell lines. TNFa inhibits cell proliferation
in a dose-dependent manner and this inhibitory effect was significantly increased by 10 microM MA (left). And MA inhibits cell proliferation in a
dose-dependent manner in the presence of a non-growth inhibitory dose of TNFa (0.1 nM) (right). Cell proliferation was evaluated by MTS
method as suggested by the manufacture. Points, means of three experiments carried out in triplicate; bars, SD. * P < 0.05,**, P < 0.01, ***, P <
0.001 versus MA or TNF alone treated group. (C) MA potentiates TNFa-mediated cell growth inhibition in AsPC-1 and BxPC-3 pancreatic cancer
cell lines in a dose-dependent manner. Cell growth was evaluated by MTS method. Points, means of three experiments carried out in triplicate;
bars, SD. * P < 0.05, **, P < 0.01, ***, P < 0.001 versus MA or TNF.alone treated group.
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Figure 2 MA potentiates TNFa-induced pancreatic cancer cell apoptosis and suppresses TNFa-induced invasion. (A) MA inhibits
TNFa-induced cell viability by Live/Dead assay. Panc-28 cells were pretreated with or without 25 microM MA for 12 h, and then incubated with
0.1 nM TNFa for 24 h. The live (green) or dead (red) cells were stained with Live and dead assay kit as mentioned in Materials and Methods.
Magnification, ×10. (B) MA potentiates cell apoptosis induced by TNFa using annexin V staining (top) and TUNEL staining (bottom). Panc-28 cells
were pretreated with or without 25 microM MA for 6 (or 12) h, and incubated with or without 0.1 nM TNFa for another 12 (or 24) h, then
stained with annexin V-FITC (or TUNEL) and analyzed by flow cytometry as mentioned in Materials and Methods. (C) MA potentiates the
cleavage of PARP and caspase-3. Panc-28 cells were pretreated with or without 25 microM MA for 6 h, and then incubated with or without 0.1
nM TNFa for the indicated time. Cell lysates were harvested and analyzed by Western blot with the indicated antibodies. (D) MA suppresses
pancreatic cancer cell invasion induced by TNFa. Panc-28 cells were seeded onto the top chambers of the transwell. After treated with 10
microM MA for 12 h, the number of cells invaded the transwell was counted as described in Materials and Methods. Columns, mean; bars, SD.
Magnification, ×10.
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proteins, PARP and caspase-3, using Western blot analy-
sis. As shown in Fig. 2C, the accumulation of cleavaged
PARP and caspase-3 was markedly increased during
incubation with TNFa and MA together, indicating that
MA can facilitate the activation of caspase and PARP
apoptotic pathway induced by TNFa.
MA suppresses TNFa-induced pancreatic cancer cell
invasion
The lethal nature of pancreatic cancer stems from its
high invasion ability and propensity to rapidly metastasis
to the lymphatic system and distant organs [3-5]. To
determine the effects of MA on pancreatic cancer cell
invasion, we performed the transwell invasion assay and
found that MA can markedly inhibit TNFa-induced
Panc-28 pancreatic cancer cell invasion, while MA alone
had no significantly inhibitory activity (Fig. 2D).
MA inhibits TNFa-induced NF-B activity in pancreatic
cancer cells
NF-B is a key regulator in cell apoptosis and TNFa-
induced NF-B activation is relatively well understood
[24]. To determine whether MA induced cell apoptosis
is mediated by NF-B, we investigated NF-B activation
using different approaches in the presence of MA.
Firstly, using EMSA assay, we demonstrated that MA
alone could suppress endogenous NF-B DNA binding
activity in a time-dependent manner and also suppress
the TNFa-induced NF-B activation in a dose-depen-
dent manner in Panc-28 cells (Fig. 3A). The strong inhi-
bitory effects of MA on TNFa-induced NF-B DNA
binding activity were further confirmed in three more dif-
ferent type pancreatic cancer cell lines Panc-1, BXPC-3
and ASPC-1 (Fig. 3B). Secondly, we tested whether MA
can suppress the in vivo DNA binding of TNFa-induced
NF-B to the COX-2 promoter using CHIP assay. We
demonstrated that TNFa induced NF-B binding to
COX-2 promoter in a time-dependent manner and that
MA markedly suppressed the binding of NF-B to the
promoter (Fig. 3C). Finally, similar results were also
obtained by NF-B-luciferase reporter gene assay. As
shown in Figure 3D, MA significantly inhibited TNFa
induced NF-B reporter gene activity in a dose-dependent
manner (Fig. 3D). Together, all of our results suggested
that MA strongly inhibited TNFa-induced NF-B activity
in pancreatic cancer cells.
MA inhibited TNFa-induced p65 nuclear translocation
and p65 phosphorylation in pancreatic cancer cells
The effects of MA on p65 nuclear translocation and
phosporylation were examined in pancreatic cancer
cells. In the absence of TNFa, the majority of p65 was
primarily located in the cytoplasm (Fig. 4A, Control).
Upon TNFa treatment, almost all p65 signals were
detected in the nucleus after 20 minutes of incubation
(Fig. 4A, TNFa). MA inhibited TNFa-induced p65
nuclear translocation (Fig. 4A, TNFa+MA). To confirm
the data generated by immunofluorescence staining, we
performed Western blot analysis of p65 in nuclear
extracts (NE) and cytoplasmic extracts (CE). As shown
in Fig. 4B, total p65 and phosphor-p65 (p-p65Ser536)
started to accumulate in a time-dependent manner
when induced by TNFa, and the accumulation peaked
in 15-30 minutes after stimulation of TNFa. On the
other hand, total p65 in cytoplasmic extracts (CE) dra-
matically decreased after 15 minute treatment by TNFa
(Fig. 4B, left). Treatment of MA inhibited TNFa
induced p65 nuclear translocation and p65 phosphoryla-
tion (Fig. 4B, right), suggesting that MA suppresses
TNFa induced NF-B nuclear translocation and activa-
tion in pancreatic cancer cells.
MA inhibits TNFa-induced IBa degradation in
pancreatic cancer cells
To understand whether treatment of MA affects TNFa-
induced upstream of NF-B/p65 pathway, we examined
TNFa-dependent IBa degradation. TNFa-induced
IBa degradation happens within 10 minutes of stimula-
tion and reached a maximum at 20 minutes, but treat-
ment of MA significantly inhibited TNFa induced IBa
degradation in pancreatic cancer cells (Fig. 4C).
MA suppresses NF-B-regulated gene expression in
pancreatic cancer cells
NF-B is known to regulate a variety of cell functions,
including apoptosis, proliferation, invasion and angio-
genesis through regulating target gene expression
[24,25]. Using Western blot analysis, we examined the
effects of MA on gene expression regulated by TNFa
treatment and NF-B activation. As shown in Fig. 5,
MA inhibited TNFa-induced gene expression in a time-
dependent manner. Specifically, MA suppressed the
expression of anti-apoptosis genes, such as Survinin,
Bcl-2, Bcl-xl, XIAP, IAP-1 (Fig. 5A), anti-proliferation
genes, such as c-Myc, COX-2, Cyclin D1 (Fig. 5B), anti-
invasion and angiogenesis related genes, such as ICAM-1,
VEGF, MMP-9 (Fig. 5C).
MA inhibits pancreatic tumor growth in a mouse
xenograft tumor model by inducing apoptosis and
suppressing NF-B-mediated anti-apoptosis protein
expression in vivo
To examine whether MA can inhibit pancreatic cancer
growth, potentiate cell apoptosis, and suppress NF-B
activity in vivo, we examined the effects of MA on the
growth of xenograft implanted pancreatic tumors in athy-
mic nu/nu mice. As shown in Fig. 6A, tumor growth was
significantly suppressed by MA in a dose-dependent
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Figure 3 MA inhibits TNFa-induced NF-B activity in pancreatic cancer cells. (A) MA suppressed endogenous NF-B DNA binding activity
(left) in a time-dependent manner and TNFa-induced NF-B activity (right) in a concentration-dependent manner. Panc-28 cells were pretreated
with indicated concentrations of MA for 6 h, incubated with or without 0.1 nM TNFa for 15 minutes, and then subjected to EMSA to examine
NF-B activation. Arrowhead indicates the DNA-binding activity of NF-B. (B)MA suppressed TNFa-induced NF-B activity in different pancreatic
cancer cell lines. Pancreatic cancer cells were pretreated with or without 25 microM MA for 6 h, and then incubated with 0.1 nM TNFa for 15
minutes. The DNA binding activity of NF-B was evaluated by EMSA. (C) MA inhibited the binding of NF-B to the COX-2 promoter in vivo.
Panc-28 cells were pretreated with 25 microM MA for 12 h and treated with 0.1 nM TNFa for the indicated time. The proteins were cross-linked
with DNA by formaldehyde and then subjected to ChIP assay using an anti-p65 antibody with the COX-2 primer. (D) MA inhibited TNFa-
induced NF-B dependant reporter gene expression. 293 cells were transiently transfected with a NF-B luciferase reporter gene. After
transfection, cells were pretreated with the indicated concentrations of MA for 24 h, and then incubated with 0.1 nM TNFa for another 24 h.
Cell supernatants were collected and assayed for luciferase activity as described in Materials and Methods. Results are expressed as fold activity
over the activity of the vector control. Column, means of three experiments carried out with triplicate; bar, SD. **, P < 0.01, ***, P < 0.001 versus
TNFa alone treated group.
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Figure 4 MA blocks TNFa-induced p65 nuclear translocation, p65 phosphorylation and IBa degradation in pancreatic cancer cells. (A)
MA inhibited TNFa-induced p65 nuclear translocation by immunofluorescence analysis. Panc-28 cells were pretreated with or without 25 microM
MA, and then stimulated with or without 0.1 nM TNFa for 20 minutes. The localization of p65 was visualized by immunofluorescence analysis as
described in materials and methods. Magnification, ×40. (B) MA inhibited TNFa-induced p65 nuclear translocation and p65 phosphorylation by
Western blot. Panc-28 cells were incubated with 25 microM MA for 6 h and treated with 0.1 nM TNFa for the indicated time. Cytoplasmic
extracts (CE) and nuclear extracts (NE) were analyzed by Western blot using the indicated antibodies. Anti-b-actin and anti-PARP antibodies were
used as controls. (C) MA inhibited TNFa-induced IBa degradation. Cells were pretreated with 25 microM MA, and then stimulated with 0.1 nM
TNFa for 20 minutes. Whole cell extracts were prepared for Western blot analysis using indicated antibodies.
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Figure 5 MA suppresses TNFa-induced NF-B downstream gene expression in pancreatic cancer cells. Panc-28 Cells were pretreated
with or without 25 microM MA for 6 h, then incubated with 0.1 nM TNFa for the indicated time, the whole cell extracts were prepared for
Western blot analysis using antibodies for proteins involved in apoptosis (A), proliferation (B), and tumor metastasis (C).
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Figure 6 MA suppresses pancreatic tumor growth, induces apoptosis, and inhibits the NF-B-regulated anti-apoptotic gene
expression in vivo. (A) MA inhibited pancreatic tumor growth in xenograft mouse model using Panc-28 pancreatic cancer cells in two different
doses (10 mg/kg or 50 mg/kg). Both tumor volume and weight significantly decreased in MA-treated groups compared to DMSO control group
in a dose-dependent manner. Column, mean; bar, SD (n = 6, **, P < 0.01, ***, P < 0.001 versus control). (B) MA had little effect on mouse body
weight. No significant difference between MA-treated groups (10 mg/kg and 50 mg/kg) and the control group. (C) MA inhibited tumor
apoptosis and suppressed the expression levels of NF-B-regulated gene expression in xenograft mouse model. Solid tumor were fixed and
embedded with paraffin. The 5 micro m sections were stained with specific TUNEL staining kit (left side), and antibodies for anti-apoptosis
proteins, Survivin and Bcl-xl (arrowheads indicate the TUNEL signals, magnification, ×10). (D) A schematic diagram of mechanism by which MA
increases pancreatic tumor susceptibility to TNFa. MA or TNFa alone can induce pancreatic cancer cell apoptosis through a caspase-dependant
pathway (left). The apoptotic effect of TNFa is attenuated by MA due to NF-B regulated anti-apoptosis gene expression (right). MA can
suppress NF-B activation therefore enhances TNFa induced apoptosis.
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manner. The average tumor volume and tumor weight
are significantly decreased in 10 mg/kg MA-treated
group and in 50 mg/kg MA-treated group in a dose-
dependent way, suggesting MA strongly inhibits tumor
growth in xenograft mouse pancreatic tumor model.
Moreover, both 10 mg/kg and 50 mg/kg MA-treated
groups had little effect on body weight at the concentra-
tion tested (Fig. 6B), suggesting little toxicity of the com-
pound at the tested concentration, which is consistent
with previous studies [22,23].
To further uncover whether MA potentiates cancer
cell apoptosis in vivo, we stained the solid tumor sec-
tions with apoptosis staining kit. As shown in Fig. 6C,
application of MA in xenograft mouse model signifi-
cantly increased apoptotic cells in a dose-dependent
manner using TUNEL assay. The number of TUNEL-
positive cells increased from 8 ± 3.2% positive nuclei in
DMSO control group to 21 ± 5.41% and 38 ± 10.17% in
10 mg/kg and 50 mg/kg MA-treated groups, respec-
tively. Furthermore, the expression levels of two NF-B-
regulated anti-apoptosis genes, Survivin and Bcl-xl were
significantly decreased (Fig. 6C) by immunohistochemis-
try staining. The decrease of Survivin and Bcl-xl expres-
sion levels is dose-dependent, suggesting that MA can
inhibit pancreatic tumor growth and induce tumor cell
apoptosis through suppression NF-B-mediated gene
expression in vivo.
Discussion
The aim of this study was to determine whether MA, a
nontoxic microchemical ingredient and widely present
in the diet, could sensitize pancreatic cancer to the
treatment of TNFa. In various pancreatic cancer cell
lines, MA or TNFa alone moderately inhibited cancer
cell growth and induced apoptosis. When combined
together, these anti-tumor cell effects were dramatically
increased. To understand the underlying mechanisms,
we demonstrate that MA could enhance TNFa induced
caspase apoptotic pathway and suppress TNFa induced
NF-B activation (Fig. 6D). MA can inhibit TNFa
induced IBa degradation, block p65 nuclear transloca-
tion and phosphorylation, and finally, down-regulate the
expression levels of NF-B-mediated genes/proteins
involved in proliferation (Cyclin D1, COX-2 and c-Myc),
apoptosis (Survivin, Bcl-2, Bcl-xl, XIAP, IAP1), invasion
(MMP-9 and ICAM-1), and angiogenesis (VEGF). In
athymic nu/nu mice model, MA suppressed pancreatic
tumor growth, induced apoptosis, and inhibited NF-B-
regulated antiapoptosis genes (Survivin and Bcl-xl).
Previous studies indicate that TNFa have multiple
roles in pancreatic cancer [13,26,27]. Several evidences
found that TNFa could induce pancreatic cancer cell
apoptosis in vitro and in vivo [11,27]. However, it is also
reported that pancreatic tumor secreting TNFa may be
the crucial trigger of tumor recurrence and metastasis
after surgical resection [8,28]. Many studies also showed
that tumor secreted-TNFa could prevent pancreatic
cancer cell from apoptosis mediated by exogenous
TNFa by activating NF-B signaling pathway [8,14].
Furthermore, the apoptosis potency of TNFa can be
increased in certain tumors when NF-B activity is
inhibited [2,13,16,27,29-32]. Therefore, inhibition of NF-
B activation by pharmacologic approaches has become
an attractive strategy for improving the anti-tumor
activity of TNFa [2,10,13,27]. In the current study, we
found that MA or TNFa alone showed moderate apop-
tosis activities in pancreatic cancer cell lines. However,
MA dramatically increased cell apoptosis and inhibited
NF-B activity induced by TNFa in various pancreatic
cancer cell lines, suggesting a synergistic effect of MA
together with TNFa. And finally, we demonstrated that
the expression levels of NF-B-mediated downstream
genes, including anti-apoptosis genes, proliferation
genes, and metastasis related genes induced by TNFa,
were all inhibited by MA in the pancreatic cancer cells.
In this study, we found that MA alone can effectively
suppress pancreatic tumor growth, induce tumor apop-
tosis, and inhibit the expression levels of NF-B-regu-
lated anti-apoptosis genes in xenograft nude mouse
models. Previous studies have shown that the secretion
of TNFa was highly increased in pancreatic tumor tis-
sues and even in serum in vivo [8,27,29]. Human plasma
levels of TNFa were significantly higher in pancreatic
adenocarcinoma patients (32.7 pg/ml) compared with
chronic pancreatitis patients (3.2 pg/ml) and control
group (<1.6 pg/ml; p < 0.01) [33], suggesting that MA
could be an effective agent in the treatment of pancrea-
tic cancer due to the high level of TNFa secretion in
the patients.
Conclusions
In summary, our data demonstrate that MA can
potentiate the anti-tumor activity of TNFa, inhibit pan-
creatic cancer proliferation, invasion, and induce tumor
cell apoptosis by increasing caspase-mediated apoptotic
activation and suppressing NF-B activity in pancreatic
tumors (Fig. 6D). These results support the conclusion
that MA together with TNFa could be a new promising
nontoxic agent in the management of pancreatic cancer.
Methods
Materials
MA was synthesized in our laboratory. The antibodies
used in this study were all obtained from Cell Signaling
Technology (Danvers, MA). The terminal deoxynucleoti-
dyl transferase (TdT)-mediated dUTP nick end labeling
(TUNEL) was obtained from Millipore Biotechnology.
Penicillin, streptomycin, MEM/F12, DMEM (high
Li et al. Molecular Cancer 2010, 9:73
http://www.molecular-cancer.com/content/9/1/73
Page 10 of 13
glucose) and fetal bovine serum (FBS) were obtained
from Invitrogen. Bacteria-derived recombinant human
TNFa, Tris, glycine, NaCl, SDS, and bovine serum albu-
min (BSA) were obtained from Sigma (St. Louis, MO).
Cell lines and cell culture
The Panc-28 cell line was a generous gift from Dr.
Bharat B. Aggarwal (The University of Texas M.D.
Anderson Cancer Center Houston, TX). Panc-1, BxPC-
3, AsPC-1 and A293 were obtained from American
Type Culture Collection. Panc-28 cells were cultured in
DME/F12 supplemented with 10% FBS. Other cells were
cultured in DMEM supplemented with 10% FBS.
Proliferation assay
The proliferation effect of MA and TNFa was determined
by the MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliu m))
method following the manual of CellTiter 96 Aqueous
One Solution Cell Proliferation assay (Promega) with
VERSAmax microplate reader (Molecular Devices). Briefly,
5000 cells were incubated with MA for 6 h in triplicate on
96-well plates and then treated with 0.1 nM TNFa for
36 h at 37°C. Thereafter, 20 microL MTS solution-I was
added to each well. After 2~4 h of incubation at 37°C,
the OD was measured at 490 nm using a 96-well
multiscanner.
Transwell invasion assay
To test the effect of MA on cell invasion activity, we
performed transwell invasion assay as previously
described {Yi, 2008 #37}. Briefly, the starved cells (1 ×
105/well) were seeded onto the top chambers of the
transwell (Corning, with an 8 micro meter pore polycar-
bonate filter insert) coated with 0.1% gelatin (Corning).
The bottom chambers were filled with DMEM/F12 with
10% FBS supplemented with 0.1 nM TNFa. The top
and bottom chamber medium contain the same concen-
tration of MA. PANC28 cells were allowed to migrate
for 12 h. Then scraped the cells on the top surface of
membrane and stained, counted the cells on the bottom
side of the membranes (migrated cells) using OLYMPUS
inverted microscope.
Live and Dead assay
To assess the cytotoxicity of MA and TNFa, we per-
formed Live/Dead assay as previously described [16].
Briefly, 1 × 105 cells were incubated with 25 microM
MA for 12 h, and then incubated with 0.1 nM TNFa
for 24 h at 37°C. Cells were stained with Live/Dead
reagent (5 microM ethidium homodimer and 5 microM
calcein-AM) and then incubated at 37°C for 30 min.
Cells were analyzed under a fluorescence microscope
(DM 4000B, Leica).
Annexin V and Tunnel assays
To detect whether MA induces pancreatic cancer cell
apoptosis, we stained the treated cells with annexin V
kit (sigma) as previously described [16]. Briefly, 1 × 106
cells were pretreated with 25 microM MA for 3 h, trea-
ted with 0.1 nM TNFa for 12 h, and then subjected to
annexin V staining. The results were analyzed with a
flow cytometer (FACSAria; BD Biosciences) Cell apopto-
sis was also measured by the TUNEL assay using an in
situ cell death detection reagent (Millipore) as pre-
viously described. Stained cells were analyzed with a
flow cytometer.
Electrophoretic mobility shift assay
To assess NF-B activation by TNFa, we performed
electrophoretic mobility shift assay (EMSA) using the
Odyssey Infrared EMSA Kit following the manufactiure
protocol. Briefly, nuclear extracts were prepared as pre-
viously described [16]. Nuclear extracts (5 micro g/sam-
ple) were incubated with NF-B IRDye™ 700 Infrared
Dye Labeled Oligonucleotides, 5’ AGTTGAGGG-
GACTTTCCCAGG C 3’ and 3’ TCAACTCCCCT-
GAAAGGGTCCG 5’ (Boldface indicates NF-B binding
sites) in reaction buffers, for 30 min at 37°C. DNA-pro-
tein complex was separated from free oligonucleotide on
6.6% native polyacrylamide gels. The gels were visualized
with Odyssey Infrared system and were quantitated
using Imagequant software (LICOR Biosciences).
NF-B-dependent luciferase reporter gene assays
The effect of MA on TNFa-induced NF-B-dependent
luciferase reporter assays were performed as previously
described [16].
Chromatin immunoprecipitation (CHIP) assay
CHIP assay was performed as described previously with
some modification. Panc-28 (2 × 107 cells) were incu-
bated with 25 microM MA for 6 h and then treated
with 0.1 nM TNFa for the indicated time. Cells were
then cross-linked with formaldehyde, quenched with
glycine, and sonicated on ice and centrifuged at 4°C.
Mixtures were incubated with anti-p65 antibody with
rotation at 4°C overnight and then incubated with 100
micro L of protein A beads at 4°C for 6 h. After gentle
centrifugation (2000 rpm), beads were resuspended in
1 mL of wash buffer, washed 3 times. Finally, immuno-
complexes were washed and eluted with elution buffer
(500 μg/ml each) at 37°C for 30 minutes. Extracted and
dissolved Immunoprecipitated DNA was prepared
for PCR assays. PCR products were run on 1.5% polya-
crylamide gel and stained with ethidium bromide.
Stained bands were visualized under UV light and
photographed. The primers corresponding to -434/-414
and -319/-337 of human COX-2 promoter sequence:
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5’ AAAGACATCTGGCGGAAACCT 3’ and 5’ AGGA-
AGCTGCCCCAATTTG 3’, were used in the PCR
reactions.
Immunocytochemical analysis of NF-B/p65 localization
The effect of MA on the nuclear translocation of p65
was examined by immunocytochemistry as previously
described. Briefly, cells were pretreated with 25 microM
MA following seeded on a gelatin-coated glass, after sti-
mulation with or without 0.1 nM TNFa for 20 minutes,
fixed with 4% paraformaldehyde after permeabilization
with 0.2% Triton X-100. After being washed in PBS,
blocked and then incubated with rabbit polyclonal anti-
human p65 antibody at a 1/25 dilution overnight incu-
bation at 4°C, washed, incubated with goat anti-rabbit
IgG-Alexa Fluor 594 (Molecular Probes) at a 1/500 dilu-
tion for 1 h, and counterstained for nuclei with DAPI
(50 ng/ml) for 5 min. Stained slides were mounted with
mounting medium purchased from Sigma-Aldrich and
analyzed under a fluorescence microscope.
Xenograft mouse model of pancreatic cancer
Xenograft mouse models were performed as described.
4-5 week-old athymic nu/nu male mice purchased from
SIBS, Shanghai. Maintain, use, and treatment of all ani-
mals in this study were in accordance with accepted
standards of the Ethics Committee at ECNU. Mice
weighing about 20 g were divided with six mice per
group. Panc-28 tumor cells were s.c. injected (3.3 × 106
cells per mouse) into the mice. After the tumors had
established (about 100 mm3), the mice were subcuta-
neous injected with 10 mg/kg or 50 mg/kg MA every
two day. The control mice were injected with DMSO.
The mice body weight and tumor sizes were recorded
every two-day and the tumor size were determined by
Vernier caliper measurements and calculated as length
× width × height. After 36 days, mice with tumors were
sacrificed.
Histology and immnohistochemistry
Tumor were removed, weighed, fixed with 10% formalin,
and embedded with paraffin. TUNEL assay was per-
formed to detect apoptotic cells using the in situ Cell
Death Detection kit from Chemicon according to the
manufacture’s instructions. The expression of Survin
and Bcl-xl were examined using an immunohistochem-
ical method described previously.
Statistical analysis
Data are represented as mean ± SD for the absolute
values as indicated in the vertical axis legend of figures.
The statistical significance of differential findings
between experiments and controls was determined by t-
test or Dunnett test as implemented by SPSS10.0
software. P values smaller than 0.05 were considered
statistically significant.
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